Insights

  • Home
  • Insights
  • PTAB Institutes Separate IPR Proceedings Filed by Codefendants, Finding that the Later IPR Proceeding Was Not Barred by 35 U.S.C. § 325(d), PTAB Litigation Blog

Share

PTAB Institutes Separate IPR Proceedings Filed by Codefendants, Finding that the Later IPR Proceeding Was Not Barred by 35 U.S.C. § 325(d), <i>PTAB Litigation Blog</i>

PTAB Institutes Separate IPR Proceedings Filed by Codefendants, Finding that the Later IPR Proceeding Was Not Barred by 35 U.S.C. § 325(d), PTAB Litigation Blog

January 31, 2017 Blog

Visit the Jones Day PTAB Litigation Blog.

On January 19, 2017, the PTAB instituted inter partes review of U.S. Patent No. 8,822,438 ("the ’438 patent") filed by Wockhardt Bio AG ("Wockhardt") (IPR2016-01582).  The ’438 patent is owned by Janssen Oncology, Inc. ("Janssen") and is the subject of several ongoing inter partes reviews, one of which was filed by Amerigen Pharm., Inc. ("Amerigen") which was instituted on May 31, 2016 (IPR2016-00286).  The ’438 patent is also being asserted in several district court proceedings against Amerigen, Wockhardt and other defendants.

Read the full article at ptablitigationblog.com.

You May Also Be Interested In

December 12, 2024 Firm Hosted

Women in IP Speaker Series: The 12 Days of Trademarks

November 20, 2024 Firm Hosted

Considerations For the Development and Licensing of Patent Portfolios

November 19, 2024 Blog

Don’t Wait To Seek Discovery Or It May Be Too Late, PTAB Litigation Blog

November 18, 2024 Alert

NIS 2 Directive: Transposition Period is Up for EU Member States

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.